Biorestorative Therapies Inc (BRTX) financial statements (2020 and earlier)

Company profile

Business Address 40 MARCUS DRIVE
MELVILLE, NY 11747
State of Incorp. DE
Fiscal Year End December 31
SIC 809 - Miscellaneous Health And Allied Services, Not (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 000000
Cash and cash equivalents 000000
Receivables 0000  
Inventory, net of allowances, customer advances and progress billings     00
Inventory     00
Other undisclosed current assets 000000
Total current assets: 010000
Noncurrent Assets
Property, plant and equipment 001100
Intangible assets, net (including goodwill) 111111
Intangible assets, net (excluding goodwill) 111111
Other undisclosed noncurrent assets 00000 
Total noncurrent assets: 112221
TOTAL ASSETS: 122221
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 244533
Accounts payable 222311
Accrued liabilities  22211
Employee-related liabilities     11
Interest and dividends payable     0 
Debt 432165
Derivative instruments and hedges, liabilities 10    
Deferred revenue and credits   0 
Other liabilities   0000
Other undisclosed current liabilities 30  (1)(1)
Total current liabilities: 986698
Noncurrent Liabilities
Long-term debt and lease obligation 100001
Long-term debt, excluding current maturities 100001
Liabilities, other than long-term debt 00000 
Accounts payable and accrued liabilities 00000 
Other undisclosed noncurrent liabilities 000  0
Total noncurrent liabilities: 101001
Total liabilities: 1097698
Stockholders' equity
Stockholders' equity attributable to parent, including: (9)(7)(5)(4)(7)(7)
Common stock 000000
Treasury stock, value    (0)(0)(0)
Additional paid in capital 554537291913
Accumulated deficit (64)(51)(42)(33)(25) 
Other undisclosed stockholders' equity attributable to parent      (20)
Total stockholders' equity: (9)(7)(5)(4)(7)(7)
TOTAL LIABILITIES AND EQUITY: 122221

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 000100
Cost of revenue
(Cost of Goods and Services Sold)
   (0)(0)(0)(0)
Other undisclosed gross profit     0 
Gross profit: 000000
Operating expenses (8)(8)(8)(8)(5)(5)
Operating loss: (8)(8)(8)(7)(5)(5)
Nonoperating expense (5)(1)(1)(1)(1)(1)
Debt instrument, convertible, beneficial conversion feature   000 
Interest and debt expense (1)(0)(0)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes  0000 
Loss from continuing operations before income taxes: (14)(9)(9)(8)(6)(6)
Income tax expense (benefit)  (1)3(3)(0) 
Net loss: (14)(11)(5)(11)(6)(6)
Other undisclosed net income (loss) attributable to parent 11(3)300
Net loss available to common stockholders, diluted: (13)(9)(9)(8)(6)(6)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (14)(11)(5)(11)(6)(6)
Comprehensive loss, net of tax, attributable to parent: (14)(11)(5)(11)(6)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: